CA2773541A1 - High affinity human antibodies to human protease-activated receptor-2 - Google Patents

High affinity human antibodies to human protease-activated receptor-2 Download PDF

Info

Publication number
CA2773541A1
CA2773541A1 CA2773541A CA2773541A CA2773541A1 CA 2773541 A1 CA2773541 A1 CA 2773541A1 CA 2773541 A CA2773541 A CA 2773541A CA 2773541 A CA2773541 A CA 2773541A CA 2773541 A1 CA2773541 A1 CA 2773541A1
Authority
CA
Canada
Prior art keywords
par
antibody
human
antigen
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2773541A
Other languages
English (en)
French (fr)
Inventor
Lynn Macdonald
Andrew J. Murphy
Nicholas J. Papadopulos
Marc R. Morra
Robert R. Salzler
Michael L. Laccroix-Fralish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA2773541A1 publication Critical patent/CA2773541A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2773541A 2009-09-09 2010-09-08 High affinity human antibodies to human protease-activated receptor-2 Abandoned CA2773541A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24078309P 2009-09-09 2009-09-09
US61/240,783 2009-09-09
US24282109P 2009-09-16 2009-09-16
US61/242,821 2009-09-16
US31783910P 2010-03-26 2010-03-26
US61/317,839 2010-03-26
PCT/US2010/048034 WO2011031695A1 (en) 2009-09-09 2010-09-08 High affinity human antibodies to human protease-activated receptor-2

Publications (1)

Publication Number Publication Date
CA2773541A1 true CA2773541A1 (en) 2011-03-17

Family

ID=43063654

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2773541A Abandoned CA2773541A1 (en) 2009-09-09 2010-09-08 High affinity human antibodies to human protease-activated receptor-2

Country Status (29)

Country Link
US (3) US8101724B2 (https=)
EP (1) EP2475684B1 (https=)
JP (2) JP5832435B2 (https=)
KR (1) KR101766701B1 (https=)
CN (1) CN102574923B (https=)
AR (1) AR078346A1 (https=)
AU (1) AU2010292342C1 (https=)
BR (1) BR112012005338A2 (https=)
CA (1) CA2773541A1 (https=)
CY (1) CY1118714T1 (https=)
DK (1) DK2475684T3 (https=)
ES (1) ES2609780T3 (https=)
HR (1) HRP20170324T1 (https=)
HU (1) HUE031725T2 (https=)
IL (1) IL218501A (https=)
JO (1) JO3246B1 (https=)
LT (1) LT2475684T (https=)
MX (1) MX2012002927A (https=)
MY (1) MY159551A (https=)
NZ (1) NZ599204A (https=)
PL (1) PL2475684T3 (https=)
PT (1) PT2475684T (https=)
SG (1) SG178976A1 (https=)
SI (1) SI2475684T1 (https=)
SM (2) SMT201700102T1 (https=)
TW (1) TWI492757B (https=)
UY (1) UY32883A (https=)
WO (1) WO2011031695A1 (https=)
ZA (1) ZA201201730B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
MX353958B (es) 2011-09-22 2018-02-07 Amgen Inc Proteinas de union al antigeno cd27l.
HK1223096A1 (zh) 2013-09-25 2017-07-21 Vertex Pharmaceuticals Incorporated 用作par-2信號通路抑制劑的咪唑並噠嗪
EP3778630A1 (en) * 2014-02-28 2021-02-17 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
US10548987B2 (en) 2015-07-31 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting CD56-positive tumors
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
WO2017083618A1 (en) * 2015-11-13 2017-05-18 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
JP2019534044A (ja) 2016-11-08 2019-11-28 クイル ピュージェット サウンド バイオセラピューティクス コーポレーション 抗ｐｄ１および抗ｃｔｌａ４抗体
MX2019010802A (es) * 2017-03-16 2019-10-30 Medimmune Ltd Anticuerpos anti-par2 y usos de los mismos.
BR112021013824A2 (pt) * 2019-01-18 2021-12-14 Janssen Biotech Inc Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
CA3136281C (en) * 2019-05-30 2024-06-25 Shandong Boan Biotechnology Co., Ltd. Antibody or chimeric antigen receptor which targets claudin 18.2
CN114599351A (zh) * 2019-11-01 2022-06-07 株式会社资生堂 以皮肤中的活性型par-2为指标的皮肤状态评价方法、par-2激活促进剂或抑制剂的筛选方法和par-2激活抑制剂
CN113248611B (zh) * 2020-02-13 2026-02-06 上海泰槿生物技术有限公司 抗bcma抗体、其药物组合物及应用
CA3173205A1 (en) * 2020-03-31 2021-10-07 Roland B. WALTER Human anti-cd33 antibodies and uses thereof
SMT202500106T1 (it) 2020-08-18 2025-05-12 Cephalon Llc Anticorpi anti-par-2 e loro metodi d'uso
AU2022340645A1 (en) * 2021-09-02 2024-02-29 Memorial Hospital For Cancer And Allied Diseases Anti-cd33 antibodies and uses thereof
AU2022340644A1 (en) * 2021-09-02 2024-02-29 Memorial Hospital For Cancer And Allied Diseases Antigen recognizing receptors targeting cd33 and uses thereof
CN114181311B (zh) * 2021-12-20 2023-06-20 华东师范大学 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用
GB202204159D0 (en) * 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2024059336A1 (en) * 2022-09-18 2024-03-21 Memorial Sloan Kettering Cancer Center Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema
CN118290572B (zh) * 2023-09-19 2026-04-07 军事科学院军事医学研究院军事兽医研究所 抗狂犬病病毒全人源抗体及其组合物与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716789A (en) 1993-07-26 1998-02-10 Cor Therapeutics, Inc. Method to determine ligands, agonist and antagonist of C140 receptor
CA2722378C (en) * 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
WO2008086069A1 (en) * 2007-01-03 2008-07-17 The General Hospital Corporation Methods of treating itch
CL2008001887A1 (es) * 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
KR20090082619A (ko) 2008-01-28 2009-07-31 주식회사 알파크립텍 다프네틴을 함유하는 가려움증 또는 염증 개선용 화장료조성물
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
EP2313110A1 (en) 2008-08-05 2011-04-27 Boehringer Ingelheim International GmbH Effectors of par-2 activation and their use in the modulation of inflammation
KR101360708B1 (ko) 2009-06-18 2014-02-07 (주)아모레퍼시픽 밤껍질 추출물을 포함하는 화장료 조성물
JP2012530699A (ja) 2009-06-18 2012-12-06 株式会社アモーレパシフィック 栗皮抽出物を含む健康食品又は薬学組成物
FR2947452B1 (fr) 2009-07-01 2012-04-20 Fabre Pierre Dermo Cosmetique L-serine et/ou l-asparagine et/ou l-valine pour prevenir et/ou au traiter des reactions inflammatoires de la peau.
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري

Also Published As

Publication number Publication date
PL2475684T3 (pl) 2017-04-28
US8101724B2 (en) 2012-01-24
SMT201700102B (it) 2017-03-08
CY1118714T1 (el) 2017-07-12
HRP20170324T1 (hr) 2017-04-21
EP2475684B1 (en) 2016-11-30
UY32883A (es) 2011-03-31
HK1166509A1 (en) 2012-11-02
US20110059095A1 (en) 2011-03-10
KR20120059611A (ko) 2012-06-08
WO2011031695A1 (en) 2011-03-17
AU2010292342C1 (en) 2015-08-27
JP6055055B2 (ja) 2016-12-27
MX2012002927A (es) 2012-08-03
AU2010292342B2 (en) 2015-04-30
JP5832435B2 (ja) 2015-12-16
US20120093824A1 (en) 2012-04-19
ES2609780T3 (es) 2017-04-24
JP2013504577A (ja) 2013-02-07
KR101766701B1 (ko) 2017-08-09
NZ599204A (en) 2014-05-30
AU2010292342A1 (en) 2012-05-03
US9028819B2 (en) 2015-05-12
EP2475684A1 (en) 2012-07-18
TW201121565A (en) 2011-07-01
AR078346A1 (es) 2011-11-02
JP2015227381A (ja) 2015-12-17
DK2475684T3 (en) 2017-03-06
SG178976A1 (en) 2012-04-27
IL218501A (en) 2017-03-30
IL218501A0 (en) 2012-07-31
US20140179903A1 (en) 2014-06-26
HUE031725T2 (en) 2017-08-28
TWI492757B (zh) 2015-07-21
US8425907B2 (en) 2013-04-23
MY159551A (en) 2017-01-13
SMT201700102T1 (it) 2017-03-08
CN102574923B (zh) 2016-12-07
LT2475684T (lt) 2017-01-25
JO3246B1 (ar) 2018-03-08
PT2475684T (pt) 2017-02-10
BR112012005338A2 (pt) 2016-11-22
ZA201201730B (en) 2012-11-28
SI2475684T1 (sl) 2017-03-31
CN102574923A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
US9028819B2 (en) Methods of alleviating itch by administering human antibodies to human protease-activated receptor 2
JP7759417B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
CA2902172C (en) Anti-il-33 antibodies and uses thereof
JP6654165B2 (ja) 抗ｔｉｅ２抗体およびその使用
US20180208656A1 (en) Anti-Prokineticin Receptor (PROKR) Antibodies and Uses Thereof
HK1166509B (en) High affinity human antibodies to human protease-activated receptor-2
EA048830B1 (ru) Полинуклеотиды, кодирующие антитела, которые связываются с лептиновым рецептором, и способ получения таких антител

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150731

FZDE Discontinued

Effective date: 20190910